Lowe Wealth Advisors LLC lifted its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 36.4% during the first quarter, HoldingsChannel reports. The firm owned 828 shares of the company’s stock after purchasing an additional 221 shares during the period. Lowe Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $147,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Family CFO Inc bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $26,000. Steward Financial Group LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth about $34,000. Advocacy Wealth Management Services LLC increased its stake in shares of Johnson & Johnson by 41.4% in the first quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company’s stock worth $41,000 after purchasing an additional 67 shares during the period. Iron Horse Wealth Management LLC increased its stake in shares of Johnson & Johnson by 29.9% in the fourth quarter. Iron Horse Wealth Management LLC now owns 265 shares of the company’s stock worth $45,000 after purchasing an additional 61 shares during the period. Finally, Gibson Wealth Advisors LLC acquired a new stake in Johnson & Johnson during the fourth quarter worth about $49,000. Institutional investors and hedge funds own 68.78% of the company’s stock.
NYSE JNJ opened at $175.74 on Thursday. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The stock’s 50 day moving average is $177.66 and its two-hundred day moving average is $173.09. The company has a market capitalization of $462.44 billion, a price-to-earnings ratio of 23.68, a PEG ratio of 3.35 and a beta of 0.66. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its quarterly earnings data on Tuesday, April 19th. The company reported $2.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.07. The company had revenue of $23.43 billion for the quarter, compared to the consensus estimate of $23.62 billion. Johnson & Johnson had a return on equity of 36.59% and a net margin of 20.90%. The company’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the previous year, the business earned $2.59 earnings per share. On average, analysts predict that Johnson & Johnson will post 10.23 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 7th. Stockholders of record on Tuesday, May 24th were issued a $1.13 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. This represents a $4.52 annualized dividend and a dividend yield of 2.57%. The ex-dividend date of this dividend was Monday, May 23rd. Johnson & Johnson’s payout ratio is presently 60.92%.
In other news, EVP Kathryn E. Wengel sold 40,000 shares of the business’s stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at approximately $12,336,803. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William Hait sold 29,699 shares of the business’s stock in a transaction that occurred on Thursday, April 21st. The stock was sold at an average price of $183.58, for a total value of $5,452,142.42. Following the completion of the transaction, the insider now directly owns 80,236 shares in the company, valued at $14,729,724.88. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock worth $13,895,302 over the last three months. 0.35% of the stock is owned by company insiders.
A number of equities research analysts recently weighed in on JNJ shares. Raymond James lifted their target price on Johnson & Johnson from $195.00 to $196.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 20th. The Goldman Sachs Group lifted their target price on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Daiwa Capital Markets started coverage on Johnson & Johnson in a research report on Wednesday. They set an “outperform” rating on the stock. Morgan Stanley decreased their target price on Johnson & Johnson from $175.00 to $173.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 6th. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $200.00 to $205.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.50.
About Johnson & Johnson (Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.